STRIDES PHARMA SCIENCE share price has zoomed 8% and is presently trading at Rs 1,103.0.
Meanwhile, the BSE HEALTHCARE index is at 40,250.9 .
Among the top gainers in the BSE HEALTHCARE index today are Pfizer (up 3.1%) and SUVEN PHARMACEUTICALS (up 2.6%).
FDC (down 2.0%) and MAX HEALTHCARE INSTITUTE (down 1.3%) are among the top losers today.
Over the last one year, STRIDES PHARMA SCIENCE has moved up from Rs 441.8 to Rs 1,103.0, registering a gain of Rs 661.2 (up 149.7%).
On the other hand, the BSE HEALTHCARE index has moved up from 26,979.9 to 40,250.9, registering a gain of 49.2% during the last 12 months.
The top gainers among the BSE HEALTHCARE index stocks during this same period were Jubilant Pharmova (up 99.2%), Lupin (up 98.5%) and GSK Pharma (up 97.6%).
Dear Reader: If You Invest in Midcap Stocks, this is for You
The BSE Sensex is at 81,407.3 (up 0.1%).
The top gainers among the BSE Sensex today are NTPC (up 4.3%) and Power Grid Corp. (up 4.0%). The most traded stocks in the BSE Sensex are Power Grid Corp. and NTPC.
In the meantime, NSE Nifty is at 24,883.3 (up 0.2%). Power Grid Corp. and NTPC are among the top gainers in NSE NIFTY.
Over the last 12 months, the BSE Sensex has moved up from 66,707.2 to 81,407.3, registering a gain of 14,700.1 points (up 22.0%).
STRIDES PHARMA SCIENCE net profit grew 239.9% YoY to Rs 801 million for the quarter ended June 2024, compared to a profit of Rs 236 million a year ago. Net sales rose 16.9% to Rs 10,875 million during the period as against Rs 9,300 million in April-June 2023.
For the year ended March 2023, STRIDES PHARMA SCIENCE reported 51.3% increase in net profit to Rs -2,309 million compared to net loss of Rs 4,743 million during FY22. Revenue of the company grew 20.1% to Rs 36,884 million during FY23.
The current Price to earnings ratio of STRIDES PHARMA SCIENCE, based on rolling 12 month earnings, stands at 121.1.
Equitymaster requests your view! Post a comment on "STRIDES PHARMA SCIENCE Gains 8%; BSE HEALTHCARE Index Down 0.0%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!